Results 221 to 230 of about 356,633 (356)

Vitexin Attenuates the Growth and Glycolysis of Acute Myeloid Leukemia Cells by Suppressing the HIF‐1α‐Modulated YAP Pathway Under Hypoxic Conditions

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Vitexin, an apigenin flavone glycoside, exhibits antitumor activity against various cancers including leukemia. Hypoxia enhances glycolysis, thereby promoting tumor growth. In this study, we aimed to explore the effects of vitexin on hypoxia‐induced growth and glycolysis in acute myeloid leukemia (AML) cells and determine the underlying ...
Ping Wang, Jia‐Jia Zhang, Fang Zhang, Xiao‐Jie Qu, Hui Zhang   +4 more
wiley   +1 more source

GAB2 couples genetic drivers and signaling networks in acute myeloid leukemia. [PDF]

J Clin Invest
Luvisotto A, Wang L.
europepmc   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

DHX9 as a prognostic biomarker and its biological roles in acute myeloid leukemia. [PDF]

BMC Cancer
Xiong Y, Chen Y, Luo H, Shi M, Wang C, Hu X, Zhu H.   +6 more
europepmc   +1 more source

The Global Burden of Leukemia, 1990–2021: A Systematic Analysis of Prevalence, DALYs, and Risk Factors From the Global Burden of Disease Study

Med Research, EarlyView.
Using data from the Global Burden of Disease Study 2021, we systematically assessed leukemia prevalence and disability‐adjusted life years (DALYs) across 204 countries and territories from 1990 to 2021, stratified by subtype, demographics, and risk factors.
Yuping Wu, Haini Zhang, Shuang Luo, Xiangmei Zhang, Mei Tan, Jinmei Chen, Pei Huang, Yan Chen, Zuochen Du   +8 more
wiley   +1 more source

Targeted and epigenetic therapies for acute myeloid leukemia treatment. [PDF]

Discov Oncol
Shokoohi M, Ghaderi M, Mokarami M, Arian H, Mohammadnabi S, Farokhi A.   +5 more
europepmc   +1 more source

Acute myeloid leukemia driven IL-3-dependent upregulation of BCL2 in non-malignant hematopoietic stem and progenitor cells increases venetoclax-induced cytopenias

Dominic Fowler-Shorten, Rebecca S Maynard, Katherine Hampton, Annalisa Altera, Matthew Markham, Martha Ehikioya, Edyta E. Wojtowicz, Kristian M. Bowles, Stuart A. Rushworth, Charlotte Hellmich   +9 more
openalex   +2 more sources

Machine Learning for Predictive Modeling in Nanomedicine‐Based Cancer Drug Delivery

Med Research, EarlyView.
The integration of AI/ML into nanomedicine offers a transformative approach to therapeutic design and optimization. Unlike conventional empirical methods, AI/ML models (such as classification, regression, and neural networks) enable the analysis of complex clinical and formulation datasets to predict optimal nanoparticle characteristics and therapeutic
Rohan Chand Sahu, Sanchit Arora, Dinesh Kumar, Ashish Kumar Agrawal   +3 more
wiley   +1 more source

A novel strategy to target metabolic dependencies in acute myeloid leukemia. [PDF]

Cell Death Dis
Balasundaram N, Palani HK, Venkatraman A, Augustin Y, Pichandi S, Regnault C, Solomon M, Rajasekaran A, Yasar M, Palani Kumar S, Radhakrishnan RN, Korula A, Kulkarni UP, Edison ES, Balasubramanian P, George B, Abraham A, Krishna S, Mathews V.   +18 more
europepmc   +1 more source

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia

Kuo‐Kai Chin, Yannis K. Valtis, Andriy Derkach, Meira Yisraeli Salman, Leora Boussi, Jenna Ciervo, Mark B. Geyer, Jae H. Park, Martin S. Tallman, Jacob L. Glass, Aaron D. Goldberg, Eytan M. Stein   +11 more
openalex   +1 more source